7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.
1. A method of treating tonic-clonic seizures in a subject with epilepsy comprising administering a therapeutically effective amount of 7-hydroxy-cannabidiol (7-OH-CBD), thereby treating tonic-clonic seizures.
2. The method of claim 1 , wherein the 7-OH-CBD is in a pure, isolated or synthetic form.
3. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of 7-hydroxy-cannabidivarin (7-OH-CBDV).
4. The method of claim 1 , wherein the 7-OH-CBD is administered as a pharmaceutical composition comprising the 7-OH-CBD with a pharmaceutically acceptable carrier.
5. The method of claim 1 , further comprising administering to the subject one or more concomitant anti-epileptic drugs (AED).
6. The method of claim 5 , wherein the one or more AED is selected from the group consisting of: clobazam; levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin.
7. The method of claim 1 , wherein the dose of 7-OH-CBD is between 1 and 2000 mg/kg.
8. The method of claim 3 , wherein the 7-OH-CBD is formulated for administration separately, sequentially or simultaneously with the 7-OH-CBDV or the combination is provided in a single dosage form.
9. The method of claim 3 , wherein the 7-OH-CBDV is in a pure, isolated or synthetic form.
10. The method of claim 3 , wherein the dose of 7-OH-CBDV is between 1 and 2000 mg/kg.
11. The method of claim 4 , wherein the pharmaceutical composition further comprises 7-hydroxy-cannabidivarin (7-OH-CBDV).
12. A pharmaceutical composition comprising 7-hydroxy-cannabidiol (7-OH-CBD) with a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition further comprises 7-hydroxy-cannabidivarin (7-OH-CBDV).
14. The pharmaceutical composition of claim 12 , wherein the 7-OH-CBD is in a pure, isolated or synthetic form.
15. The pharmaceutical composition of claim 12 , wherein the composition is formulated to have a dose of 7-OH-CBD between 1 and 2000 mg/kg.
16. The pharmaceutical composition of claim 13 , wherein the 7-OH-CBD is formulated for administration separately, sequentially or simultaneously with the 7-OH-CBDV.
17. The pharmaceutical composition of claim 13 , wherein the 7-OH-CBD and 7-OH-CBDV are provided in a single dosage form.
18. The method of claim 1 , wherein the 7-OH-CBD is administered in an oral solution comprising the 7-OH-CBD and a pharmaceutically acceptable carrier.
19. The method of claim 1 , wherein the administering treats myoclonic jerks.
20. The method of claim 1 , wherein the administering reduces seizure severity.
21. The method of claim 1 , wherein the administering reduces latency to seizure onset.